Franceschi, Enrico <br/><br/>
Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?  [electronic resource] 

 -  Journal of neuro-oncology  Sep 2018 
 - 383-388 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1573-7373 
<br/><br/><label>Standard No.: </label>10.1007/s11060-018-2873-x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acetanilides<br/>Adult<br/>Aged<br/>Antineoplastic Agents, Immunological--adverse effects<br/>Bevacizumab--adverse effects<br/>Biomarkers, Tumor--genetics<br/>Brain Neoplasms--drug therapy<br/>DNA Methylation<br/>DNA Modification Methylases--genetics<br/>DNA Repair Enzymes--genetics<br/>Female<br/>Follow-Up Studies<br/>Glioblastoma--drug therapy<br/>Humans<br/>Male<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Pyrroles<br/>Quinolines<br/>Retreatment<br/>Survival Analysis<br/>Treatment Outcome<br/>Tumor Suppressor Proteins--genetics<br/>Young Adult